Tag Archives: endothelial growth factor receptor
First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged carboplatin, endothelial growth factor receptor, erlotinib, gemcitabine, Gemzar, non–small cell lung carcinoma, NSCLC, OPTIMAL, progression-free, Survival, Tarceva
Comments Off on First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population